52-Week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. (13th March 2011)

• Record Type: Journal Article
• Authors: Reinisch, W; Sandborn, W J; Kumar, A; Pollack, P F; Lazar, A; Thakkar, R B
• Is Part Of: Gut. Volume 60:(2011)Supplement 1
• Page Start: A139
• Page End: A140
• Publication Date: 2011-03-13
• Subjects: adalimumab -- clinical trial -- ulcerative colitis; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gut.2011.239301.295
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Introduction: We report week-52 results from an open-label extension that assessed the efficacy and safety of adalimumab (ADA) in anti-TNF–naïve patients with moderately to severely active ulcerative colitis (UC). Methods: Patients were adults with UC (Mayo scores ≥6 points and endoscopic subscores ≥2 points) despite treatment with corticosteroids and/or immunosuppressants. After an 8-week, randomised, placebo-controlled period, patients could enter an open-label extension to receive ADA 40 mg every other week (eow) as maintenance therapy through week 52. Data were analyzed with non-responder imputation (NRI); missing scores and values after adjustment to weekly dosing (for flares/non-response) were imputed as treatment failures. Modified NRI (mNRI) analyses (post-hoc), which did not count patients who dose escalated as failures, and as-observed analyses were also performed. Results: Of 390 patients in the primary analysis population, 360 received open-label ADA eow and 117 had their dosages increased to weekly ADA. Mean/median changes in Mayo (0–12) and partial Mayo (0–9) scores from baseline to week 52 (observed values, N=274) were –5.0/–5.0 and –3.7/–4.0, respectively (all p<0.001). The table 1 summarises rates of clinical remission and other secondary end points at week 52. Remission rates at week 52 were 25.6% (NRI) and 29.5% (mNRI). No deaths or cases of tuberculosis were reported. Conclusion: Treatment with open-label ADA 40-mg eow/weekly generally maintained clinical remission and other efficacy end points in patients with moderately to severely active UC. The safety profile in UC was consistent with the known safety profile of ADA.